TOVX Theriva Biologics, Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 894158 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY66.7%
TTM EPS YoY-44.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-99.8%
ROA-28.0%
ROIC (approx.)-956.5%
Asset turnover—
Leverage & solvency
Liabilities / assets65.9%
Debt / equity0.00x
Current ratio1.21x
Interest coverage-138.77x
Cash quality & payout
Operating cash flow / net income1.29x
Accruals ratio8.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-12-31 | FY2024*2024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $8.60M | $12.03M |
| SG&A expense | $15.45M | $7.40M |
| Operating income | -$24.05M | -$26.35M |
| Interest expense | $61,000 | $6,000 |
| Pretax income | -$23.74M | -$25.65M |
| Income tax | — | $0 |
| Net income | -$23.74M | -$25.65M |
| EBITDA | -$23.94M | -$26.21M |
| EPS (basic) | -2.08 | -19.03 |
| EPS (diluted) | -2.08 | -19.03 |
| Weighted avg. shares (diluted) | 12.14M | 1.35M |
| Balance sheet | ||
| Cash & equivalents | $13.06M | $11.71M |
| Current assets | $17.47M | $16.28M |
| PP&E, net | $222,000 | $270,000 |
| Goodwill | — | $0 |
| Intangibles | $19.62M | $17.36M |
| Total assets | $38.24M | $35.35M |
| Current liabilities | $10.01M | $7.58M |
| Long-term debt | $1.67M | $92,000 |
| Total debt | $1.67M | $92,000 |
| Total liabilities | $22.86M | $16.29M |
| Shareholders' equity | $15.38M | $19.07M |
| Net debt | -$11.38M | -$11.61M |
| Shares outstanding | 35.69M | 2.78M |
| Cash flow statement | ||
| Operating cash flow | -$16.67M | -$16.94M |
| Capital expenditure | $35,000 | $1,000 |
| Free cash flow | -$16.70M | -$16.94M |
| Investing cash flow | -$35,000 | -$1,000 |
| Financing cash flow | $18.19M | $5.50M |
| Depreciation & amortization | $108,000 | $137,000 |
| Stock-based compensation | $654,000 | $671,000 |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.